company

Vision

Since its establishment in 2015, Rophibio has been dedicated to pioneering the development of groundbreaking biopharmaceuticals, aspiring to bring renewed hope and vitality to the field. Embracing the belief that healing should reach all places of affliction, Rophibio has consistently pursued innovative technological advancements in the biosimilar domain.
With the accumulated prowess in research and development since its inception, Rophibio is now advancing towards the conclusive phase of biosimilar development, drawing from its successful track record in development and marketing. 
 
Throughout this journey, the company has strategically aligned its talent pool across Research and Development, Product Development, and Business Development while leveraging a robust network, exemplifying an innovative management approach as a biosimilar development company.
 
The biosimilar market is poised for rapid expansion, presenting Rophibio with significant opportunities. Additionally, this evolving landscape will necessitate changes from Rophibio, not only to fulfill the pressing societal obligation of efficaciously and economically treating patients but also to carve new pathways beyond this commitment, adapting to the forthcoming changes in the field. 
CEO, Rophibio Inc. 
Stanley SeungSuh Hong